Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis
Ikuo Hirano(Northwestern University), Allen Radin(Regeneron (United States)), Alain Schoepfer(University Hospital of Lausanne), Evan S. Dellon(University of North Carolina at Chapel Hill), Ekaterina Safroneeva(University of Bern), Jennifer D. Hamilton(Regeneron (United States)), Kathryn A. Peterson(University of Utah), Gary W. Falk(Hospital of the University of Pennsylvania), Margaret H. Collins(Cincinnati Children's Hospital Medical Center), Mirna Chehade(Icahn School of Medicine at Mount Sinai), Bolanle Akinlade(Regeneron (United States)), Leda Mannent(Sanofi (France)), Neil M.H. Graham(UK Dementia Research Institute), Neil Stahl(Arthritis and Rheumatism Associates), George D. Yancopoulos(Regeneron (United States)), Marc E. Rothenberg(Cincinnati Children's Hospital Medical Center), Qiong Zhao(Regeneron (United States)), Gianluca Pirozzi(Sanofi (United States)), Zhen Chen(Ningbo University), Brian N. Swanson(Sanofi (United States)), Yehudith Assouline-Dayan(University of Iowa Hospitals and Clinics)
Cited by 448
Related Papers
Vascular-specific growth factors and blood vessel formation
|Nature|2000|3.7k
Eosinophilic esophagitis: Updated consensus recommendations for children and adults
|Journal of Allergy and Clinical Immunology|2011|2.1k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
Burden of Gastrointestinal Disease in the United States: 2012 Update
|Gastroenterology|2012|2k
VEGF-Trap: A VEGF blocker with potent antitumor effects
|Proceedings of the National Academy of Sciences|2002|1.7k